GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Silo Wellness Inc (XCNQ:SILO) » Definitions » COGS-to-Revenue

Silo Wellness (XCNQ:SILO) COGS-to-Revenue : 1.23 (As of Jul. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Silo Wellness COGS-to-Revenue?

Silo Wellness's Cost of Goods Sold for the three months ended in Jul. 2023 was C$0.12 Mil. Its Revenue for the three months ended in Jul. 2023 was C$0.10 Mil.

Silo Wellness's COGS to Revenue for the three months ended in Jul. 2023 was 1.23.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Silo Wellness's Gross Margin % for the three months ended in Jul. 2023 was -23.16%.


Silo Wellness COGS-to-Revenue Historical Data

The historical data trend for Silo Wellness's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silo Wellness COGS-to-Revenue Chart

Silo Wellness Annual Data
Trend Oct20 Oct21 Oct22
COGS-to-Revenue
8.00 3.23 0.63

Silo Wellness Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.82 0.23 0.23 1.23

Silo Wellness COGS-to-Revenue Calculation

Silo Wellness's COGS to Revenue for the fiscal year that ended in Oct. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.292 / 0.46
=0.63

Silo Wellness's COGS to Revenue for the quarter that ended in Jul. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.117 / 0.095
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silo Wellness  (XCNQ:SILO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Silo Wellness's Gross Margin % for the three months ended in Jul. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.117 / 0.095
=-23.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Silo Wellness COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Silo Wellness's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Silo Wellness (XCNQ:SILO) Business Description

Traded in Other Exchanges
N/A
Address
200 Consumers Road, Suite 702, Toronto, ON, CAN, M2J 4R4
Silo Wellness Inc operates psychedelic clinics and develops legal functional mushroom consumer products. It is focused on health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.
Executives
Michael Hartman Director